A detailed history of Envestnet Asset Management Inc transactions in Axonics, Inc. stock. As of the latest transaction made, Envestnet Asset Management Inc holds 10,241 shares of AXNX stock, worth $726,906. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,241
Previous 9,743 5.11%
Holding current value
$726,906
Previous $655,000 8.85%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

BUY
$67.3 - $69.67 $33,515 - $34,695
498 Added 5.11%
10,241 $713,000
Q2 2024

Aug 08, 2024

SELL
$66.47 - $69.65 $51,580 - $54,048
-776 Reduced 7.38%
9,743 $655,000
Q1 2024

May 13, 2024

SELL
$56.67 - $69.36 $552,362 - $676,051
-9,747 Reduced 48.1%
10,519 $725,000
Q4 2023

Feb 13, 2024

BUY
$49.38 - $63.75 $473,702 - $611,553
9,593 Added 89.88%
20,266 $1.26 Million
Q3 2023

Nov 13, 2023

SELL
$48.64 - $62.51 $164,500 - $211,408
-3,382 Reduced 24.06%
10,673 $598,000
Q2 2023

Aug 04, 2023

SELL
$47.99 - $60.21 $1.24 Million - $1.55 Million
-25,768 Reduced 64.71%
14,055 $709,000
Q1 2023

May 11, 2023

BUY
$52.6 - $67.34 $1.15 Million - $1.48 Million
21,955 Added 122.87%
39,823 $2.17 Million
Q4 2022

Feb 07, 2023

SELL
$59.56 - $76.6 $8,159 - $10,494
-137 Reduced 0.76%
17,868 $1.12 Million
Q3 2022

Nov 10, 2022

BUY
$57.96 - $78.12 $455,739 - $614,257
7,863 Added 77.53%
18,005 $1.27 Million
Q2 2022

Aug 03, 2022

BUY
$39.5 - $64.42 $144,609 - $235,841
3,661 Added 56.49%
10,142 $575,000
Q1 2022

May 04, 2022

SELL
$43.74 - $62.76 $101,170 - $145,163
-2,313 Reduced 26.3%
6,481 $406,000
Q4 2021

Feb 04, 2022

BUY
$50.01 - $73.35 $179,335 - $263,033
3,586 Added 68.86%
8,794 $492,000
Q3 2021

Oct 07, 2021

BUY
$59.21 - $78.66 $308,365 - $409,661
5,208 New
5,208 $339,000

Others Institutions Holding AXNX

About Axonics, Inc.


  • Ticker AXNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 49,123,600
  • Market Cap $3.49B
  • Description
  • Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention...
More about AXNX
Track This Portfolio

Track Envestnet Asset Management Inc Portfolio

Follow Envestnet Asset Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Envestnet Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Envestnet Asset Management Inc with notifications on news.